A 5-year-old girl case of spastic paraplegia type 56, a mutation in the CYP2U1 gene
DOI:
https://doi.org/10.18203/2349-3291.ijcp20240676Keywords:
CYP2U1 gene mutation, Case reports, Hereditary spastic paraplegia, Spastic paraplegia type 56Abstract
This case report details the presentation, diagnosis, and management of a 5-year-old girl from Saudi Arabia with Spastic Paraplegia Type 56 (SPG56) resulting from a novel mutation in the CYP2U1 gene. SPG56, a rare form of hereditary spastic paraplegia, exhibits genetic variability, impacting neurological and extra-neurological functions. The patient's clinical course involved a fall at age 2, subsequent motor deterioration, cognitive delays, and spasticity. Comprehensive diagnostic evaluations, including genetic testing, identified a homozygous likely pathogenic variant in CYP2U1. Despite outpatient therapy, the patient underwent a four-week intensive rehabilitation course to address spasticity and enhance daily living activities. This case highlights the challenges in diagnosing and managing SPG56 and underscores the importance of genetic testing in complex neurodegenerative cases.
Metrics
References
Leeson HC, Goh D, Coman D, Wolvetang EJ. Generation of iPSC lines from hereditary spastic paraplegia 56 (SPG56) patients and family members carrying CYP2U1 mutations. Stem Cell Res. 2022;64: 102917.
Tesson C, Nawara M, Salih MAM, Rossignol R, Zaki MS, Al Balwi M, et al. Alteration of Fatty-Acid-Metabolizing Enzymes Affects Mitochondrial Form and Function in Hereditary Spastic Paraplegia. Am J Human Genet. 2012;91(6):1051-64.
Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126(3):307-28.
Panda P, Sharawat I, Dawman L. Spastic paraplegia-56 due to a novel CYP2U1 truncating mutation in an Indian boy: A new report and literature review. J Pediatr Neurosci. 2021;16(1):71.
Durand CM, Dhers L, Tesson C, Tessa A, Fouillen L, Jacqueré S, et al. CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. Hum Mutat. 2017;39(1):140-51.
Kariminejad A, Schöls L, Schüle R, Tonekaboni SH, Abolhassani A, Fadaee M, et al. CYP2U1 mutations in two Iranian patients with activity induced dystonia, motor regression and spastic paraplegia. Eur J Paediatr Neurol. 2016;20(5):782-7.
Schüle R, Wiethoff S, Martus P, Karle KN, Otto S, Klebe S, et al. Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol. 2016;79(4):646-58.
Citterio A, Arnoldi A, Panzeri E, DAngelo MG, Filosto M, Dilena R, et al. Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis. J Neurol. 2013;261(2):373-81.
Masciullo M, Tessa A, Perazza S, Santorelli FM, Perna A, Silvestri G. Hereditary spastic paraplegia: Novel mutations and expansion of the phenotype variability in SPG56. Eur J Paediatr Neurol. 2016; 20(3):444-8.
Leonardi L, Ziccardi L, Marcotulli C, Rubegni A, Longobardi A, Serrao M, et al. Pigmentary degenerative maculopathy as prominent phenotype in an Italian SPG56/CYP2U1 family. J Neurol. 2016; 263(4):781-3.
Kamate M, Detroja M. Clinico-investigative profile of hereditary spastic paraplegia in children. Ann Indian Acad Neurol. 2019;22(3):341.
Samaddar S, Kaur P, Rajagopal KV, Girisha KM, Shukla A, Sharma S. Spastic Paraplegia Type 56 in a Young Child. Indian J Pediatr. 2020;87(8):650-1.